In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Travere Therapeutics, Inc.

https://travere.com/

Latest From Travere Therapeutics, Inc.

Novartis Bookends October With Two IgAN Successes

A Phase III hit moves atrasentan a step closer to the market but the drug will have to sell very well to justify the billions Novartis paid for its originator.

Renal Clinical Trials

Santhera’s Vamorolone For DMD Among Orphan Drugs Up For EU Marketing Decision

The European Medicines Agency is this week due to decide whether to recommend pan-EU marketing authorization for a number of new products.

BioPharmaceutical Cancer

Muted APPLAUSE For Novartis In IgAN

A Phase III hit is always nice but a lot more information will be required to judge iptacopan’s market potential.

Clinical Trials Renal

Travere Hopes For FDA Full Approval Despite Filspari Trial Endpoint Miss

The company said the “totality of data” from the confirmatory PROTECT trial in IgA nephropathy showed the drug slowed decline in kidney function.

Clinical Trials FDA
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Desert Gateway, Inc.
    • Kyalin Biosciences, Inc.
    • Manchester Pharmaceuticals LLC.
    • Orphan Technologies Ltd.
    • Retrophin, Inc.
UsernamePublicRestriction

Register